Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
Mais filtros

Bases de dados
Tipo de documento
Intervalo de ano de publicação
1.
Pharmacoeconomics ; 40(7): 699-714, 2022 07.
Artigo em Inglês | MEDLINE | ID: mdl-35779197

RESUMO

BACKGROUND AND AIMS: Coronavirus disease 2019 (COVID-19) imposes a substantial and ongoing burden on the US healthcare system and society. Molnupiravir is a new oral antiviral for treating COVID-19 in outpatient settings. This study evaluated the cost-effectiveness profile of molnupiravir versus best supportive care in the treatment of adult patients with mild-to-moderate COVID-19 at risk of progression to severe disease, from a US payer's perspective. METHODS: The model was developed using a decision tree for the short-term acute phase of COVID-19 and a Markov state transition model for the long-term post-acute phase. This model compared molnupiravir with best supportive care as consistent with the MOVe-OUT trial. Costs were reported in 2021 US dollars. Transition probabilities were derived from the phase III MOVe-OUT trial and the TriNetX real-world electronic health records database. Costs were derived from the TriNetX database and utility values from a de novo, vignette-based utility study. Deterministic and probabilistic sensitivity analyses (DSA/PSA) were conducted. Primary outcomes included proportion hospitalized, proportion who died overall and by highest healthcare setting at the end of the acute phase, quality-adjusted life-years (QALYs), and incremental costs per QALY gained over a lifetime (100 years) horizon, discounted at 3% annually and assessed at a willingness-to-pay (WTP) threshold of $100,000 per QALY. RESULTS: In this model, the use of molnupiravir led to an increase in QALYs (0.210) and decrease in direct total medical costs (-$895) per patient across a lifetime horizon, compared with best supportive care in COVID-19 outpatients. Molnupiravir was the dominant intervention when compared with best supportive care. Patients treated with molnupiravir were less likely to be hospitalized (6.38% vs. 9.20%) and more likely to remain alive (99.88% vs. 98.71%) during the acute phase. Through DSA, molnupiravir treatment effect of hospitalization reduction was identified to be the most influential parameter, and through PSA, molnupiravir remained dominant in 84% of the total simulations and, overall, 100% cost effective. CONCLUSION: This analysis suggests that molnupiravir is cost effective compared with best supportive care for the treatment of adult outpatients with COVID-19. However, our study was limited by the unavailability of the most recent information on the rapidly evolving pandemic, including new viral variants, patient populations affected, and changes in standards of care. Further research should explore the impact of vaccination on the cost effectiveness of molnupiravir and other therapies, based on real-world data, to account for these changes, including the impact of vaccination and immunity.


Assuntos
COVID-19 , Pacientes Ambulatoriais , Adulto , Análise Custo-Benefício , Citidina/análogos & derivados , Humanos , Hidroxilaminas , Masculino , Antígeno Prostático Específico , Anos de Vida Ajustados por Qualidade de Vida
2.
Nature ; 603(7899): 25-27, 2022 03.
Artigo em Inglês | MEDLINE | ID: mdl-35233098

Assuntos
Antivirais/uso terapêutico , Tratamento Farmacológico da COVID-19 , Ensaios Clínicos como Assunto , Reposicionamento de Medicamentos , Interações Hospedeiro-Patógeno/efeitos dos fármacos , SARS-CoV-2/efeitos dos fármacos , Monofosfato de Adenosina/administração & dosagem , Monofosfato de Adenosina/análogos & derivados , Monofosfato de Adenosina/uso terapêutico , Administração Oral , Alanina/administração & dosagem , Alanina/análogos & derivados , Alanina/uso terapêutico , Animais , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/uso terapêutico , Anticorpos Neutralizantes/administração & dosagem , Anticorpos Neutralizantes/economia , Anticorpos Neutralizantes/uso terapêutico , Antivirais/administração & dosagem , Antivirais/farmacologia , COVID-19/economia , COVID-19/imunologia , COVID-19/mortalidade , COVID-19/virologia , Vacinas contra COVID-19 , Citidina/análogos & derivados , Citidina/uso terapêutico , Depsipeptídeos/farmacologia , Depsipeptídeos/uso terapêutico , Dexametasona/administração & dosagem , Dexametasona/uso terapêutico , Combinação de Medicamentos , Sinergismo Farmacológico , Ésteres/farmacologia , Ésteres/uso terapêutico , Guanidinas/farmacologia , Guanidinas/uso terapêutico , Hospitalização , Humanos , Hidroxilaminas/uso terapêutico , Internacionalidade , Lactamas/uso terapêutico , Leucina/uso terapêutico , Camundongos , National Institutes of Health (U.S.)/organização & administração , Nitrilas/uso terapêutico , Fator 1 de Elongação de Peptídeos/antagonistas & inibidores , Peptídeos Cíclicos/farmacologia , Peptídeos Cíclicos/uso terapêutico , Prolina/uso terapêutico , Inibidores de Proteases/farmacologia , Inibidores de Proteases/uso terapêutico , RNA Polimerase Dependente de RNA/antagonistas & inibidores
4.
Nature ; 601(7894): 496, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-35064230

Assuntos
Antivirais/uso terapêutico , Tratamento Farmacológico da COVID-19 , COVID-19/virologia , Desenvolvimento de Medicamentos/tendências , Farmacorresistência Viral , Pesquisadores , SARS-CoV-2/efeitos dos fármacos , Monofosfato de Adenosina/administração & dosagem , Monofosfato de Adenosina/análogos & derivados , Monofosfato de Adenosina/farmacologia , Monofosfato de Adenosina/uso terapêutico , Administração Oral , Alanina/administração & dosagem , Alanina/análogos & derivados , Alanina/farmacologia , Alanina/uso terapêutico , Antivirais/administração & dosagem , Antivirais/farmacologia , Antivirais/provisão & distribuição , COVID-19/mortalidade , COVID-19/prevenção & controle , Vacinas contra COVID-19/provisão & distribuição , Citidina/administração & dosagem , Citidina/análogos & derivados , Citidina/farmacologia , Citidina/uso terapêutico , Aprovação de Drogas , Combinação de Medicamentos , Farmacorresistência Viral/efeitos dos fármacos , Farmacorresistência Viral/genética , Quimioterapia Combinada , Hospitalização/estatística & dados numéricos , Humanos , Hidroxilaminas/administração & dosagem , Hidroxilaminas/farmacologia , Hidroxilaminas/uso terapêutico , Lactamas/administração & dosagem , Lactamas/farmacologia , Lactamas/uso terapêutico , Leucina/administração & dosagem , Leucina/farmacologia , Leucina/uso terapêutico , Adesão à Medicação , Terapia de Alvo Molecular , Mutagênese , Nitrilas/administração & dosagem , Nitrilas/farmacologia , Nitrilas/uso terapêutico , Prolina/administração & dosagem , Prolina/farmacologia , Prolina/uso terapêutico , Parcerias Público-Privadas/economia , Ritonavir/administração & dosagem , Ritonavir/farmacologia , Ritonavir/uso terapêutico , SARS-CoV-2/enzimologia , SARS-CoV-2/genética
9.
Nature ; 592(7854): 340-343, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33854246
10.
Sci Rep ; 9(1): 5300, 2019 03 28.
Artigo em Inglês | MEDLINE | ID: mdl-30923342

RESUMO

Priming haematopoietic stem/progenitor cells (HSPCs) in vitro with specific chromatin modifying agents and cytokines under serum-free-conditions significantly enhances engraftable HSC numbers. We extend these studies by culturing human CD133+ HSPCs on nanofibre scaffolds to mimic the niche for 5-days with the HDAC inhibitor Scriptaid and cytokines. Scriptaid increases absolute Lin-CD34+CD38-CD45RA-CD90+CD49f+ HSPC numbers, while concomitantly decreasing the Lin-CD38-CD34+CD45RA-CD90- subset. Hypothesising that Scriptaid plus cytokines expands the CD90+ subset without differentiation and upregulates CD90 on CD90- cells, we sorted, then cultured Lin-CD34+CD38-CD45RA-CD90- cells with Scriptaid and cytokines. Within 2-days and for at least 5-days, most CD90- cells became CD90+. There was no significant difference in the transcriptomic profile, by RNAsequencing, between cytokine-expanded and purified Lin-CD34+CD38-CD45RA-CD49f+CD90+ cells in the presence or absence of Scriptaid, suggesting that Scriptaid maintains stem cell gene expression programs despite expansion in HSC numbers. Supporting this, 50 genes were significantly differentially expressed between CD90+ and CD90- Lin-CD34+CD38-CD45RA-CD49f+ subsets in Scriptaid-cytokine- and cytokine only-expansion conditions. Thus, Scriptaid treatment of CD133+ cells may be a useful approach to expanding the absolute number of CD90+ HSC, without losing their stem cell characteristics, both through direct effects on HSC and potentially also conversion of their immediate CD90- progeny into CD90+ HSC.


Assuntos
Doenças Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas/métodos , Células-Tronco Hematopoéticas/efeitos dos fármacos , Hidroxilaminas/farmacologia , Quinolinas/farmacologia , Transcriptoma/efeitos dos fármacos , Técnicas de Cultura de Células , Diferenciação Celular/efeitos dos fármacos , Diferenciação Celular/genética , Células Cultivadas , Meios de Cultura Livres de Soro , Sangue Fetal/citologia , Células-Tronco Hematopoéticas/metabolismo , Humanos , RNA-Seq , Análise de Célula Única , Antígenos Thy-1/genética , Antígenos Thy-1/metabolismo
11.
Toxins (Basel) ; 11(2)2019 02 06.
Artigo em Inglês | MEDLINE | ID: mdl-30736322

RESUMO

Snakebite with hemotoxic venom continues to be a major source of morbidity and mortality worldwide. Our laboratory has characterized the coagulopathy that occurs in vitro in human plasma via specialized thrombelastographic methods to determine if venoms are predominantly anticoagulant or procoagulant in nature. Further, the exposure of venoms to carbon monoxide (CO) or O-phenylhydroxylamine (PHA) modulate putative heme groups attached to key enzymes has also provided mechanistic insight into the multiple different activities contained in one venom. The present investigation used these techniques to characterize fourteen different venoms obtained from snakes from North, Central, and South America. Further, we review and present previous thrombelastographic-based analyses of eighteen other species from the Americas. Venoms were found to be anticoagulant and procoagulant (thrombin-like activity, thrombin-generating activity). All prospectively assessed venom activities were determined to be heme-modulated except two, wherein both CO and its carrier molecule were found to inhibit activity, while PHA did not affect activity (Bothriechis schlegelii and Crotalus organus abyssus). When divided by continent, North and Central America contained venoms with mostly anticoagulant activities, several thrombin-like activities, with only two thrombin-generating activity containing venoms. In contrast, most venoms with thrombin-generating activity were located in South America, derived from Bothrops species. In conclusion, the kinetomic profiles of venoms obtained from thirty-two Pan-American Pit Viper species are presented. It is anticipated that this approach will be utilized to identify clinically relevant hemotoxic venom enzymatic activity and assess the efficacy of locally delivered CO or systemically administered antivenoms.


Assuntos
Anticoagulantes/farmacologia , Coagulação Sanguínea/efeitos dos fármacos , Coagulantes/farmacologia , Venenos de Crotalídeos/farmacologia , Crotalinae , Animais , Anticoagulantes/química , América Central , Coagulantes/química , Venenos de Crotalídeos/química , Humanos , Hidroxilaminas/farmacologia , Cinética , América do Norte , Compostos Organometálicos/farmacologia , Plasma/efeitos dos fármacos , Plasma/fisiologia , América do Sul , Tromboelastografia
12.
Sci Rep ; 7(1): 14794, 2017 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-29093547

RESUMO

MS-based proteomic analysis was combined with in silico quantum mechanical calculations to improve understanding of protein adduction by N-phenylhydroxylamine (PhNHOH) and nitrosobenzene (NOB), metabolic products of aniline. In vitro adduction of model peptides containing nucleophilic sidechains (Cys, His, and Lys) and selected proteins (bovine and human hemoglobin and ß-lactoglobulin-A) were characterized. Peptide studies identified the Cys thiolate as the most reactive nucleophile for these metabolites, a result consistent with in silico calculations of reactivity parameters. For PhNHOH, sulfinamides were identified as the primary adduction products, which were stable following tryptic digestion. Conversely, reactions with NOB yielded an additional oxidized adduct, the sulfonamide. In vitro exposure of human whole blood to PhNHOH and NOB demonstrated that only sulfinamides were formed. In addition to previously reported adduction of ß93Cys of human Hb, two novel sites of adduction were found; α104Cys and ß112Cys. We also report CD and UV-Vis spectroscopy studies of adducted human Hb that revealed loss of α-helical content and deoxygenation. The results provide additional understanding of the covalent interaction of aromatic amine metabolites with protein nucleophiles.


Assuntos
Compostos de Anilina/química , Hemoglobinas/química , Hidroxilaminas/química , Compostos Nitrosos/química , Animais , Bovinos , Humanos , Oxirredução , Domínios Proteicos
13.
Cell Rep ; 16(11): 2802-2810, 2016 09 13.
Artigo em Inglês | MEDLINE | ID: mdl-27626651

RESUMO

Drugs that recapitulate aspects of the exercise adaptive response have the potential to provide better treatment for diseases associated with physical inactivity. We previously observed reduced skeletal muscle class IIa HDAC (histone deacetylase) transcriptional repressive activity during exercise. Here, we find that exercise-like adaptations are induced by skeletal muscle expression of class IIa HDAC mutants that cannot form a corepressor complex. Adaptations include increased metabolic gene expression, mitochondrial capacity, and lipid oxidation. An existing HDAC inhibitor, Scriptaid, had similar phenotypic effects through disruption of the class IIa HDAC corepressor complex. Acute Scriptaid administration to mice increased the expression of metabolic genes, which required an intact class IIa HDAC corepressor complex. Chronic Scriptaid administration increased exercise capacity, whole-body energy expenditure and lipid oxidation, and reduced fasting blood lipids and glucose. Therefore, compounds that disrupt class IIa HDAC function could be used to enhance metabolic health in chronic diseases driven by physical inactivity.


Assuntos
Proteínas Correpressoras/metabolismo , Metabolismo Energético , Histona Desacetilases/metabolismo , Metabolismo dos Lipídeos , Animais , Domínio Catalítico , Linhagem Celular , Metabolismo Energético/efeitos dos fármacos , Metabolismo Energético/genética , Regulação da Expressão Gênica/efeitos dos fármacos , Hidroxilaminas/administração & dosagem , Hidroxilaminas/farmacologia , Metabolismo dos Lipídeos/efeitos dos fármacos , Metabolismo dos Lipídeos/genética , Fatores de Transcrição MEF2/genética , Fatores de Transcrição MEF2/metabolismo , Camundongos , Mutação/genética , Oxirredução , Condicionamento Físico Animal , Ligação Proteica/efeitos dos fármacos , Quinolinas/administração & dosagem , Quinolinas/farmacologia , Transcrição Gênica/efeitos dos fármacos
14.
Angew Chem Int Ed Engl ; 53(8): 2034-6, 2014 Feb 17.
Artigo em Inglês | MEDLINE | ID: mdl-24470434

RESUMO

Adding value: The catalytic hydroamination of alkenes with amines holds promise to rapidly deliver value-added chiral amines from simple and accessible starting materials. The use of mild, Cu-catalyzed electrophilic amination strategies for the regioselective preparation of both linear and chiral branched amines is highlighted.


Assuntos
Alcenos/química , Cobre/química , Hidroxilaminas/química , Aminação , Catálise , Cadeias de Markov , Estereoisomerismo
15.
J Pharm Pharmacol ; 64(8): 1099-106, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22775213

RESUMO

OBJECTIVES: The aim was to examine the biological activity of 5-methoxytryptamine derivatives at the 5-hydroxytryptamine (5-HT)(4) receptor to explore the effect of substitution on the aliphatic amine of the 5-methoxyamine scaffold. METHODS: Three compounds were tested for affinity at the 5-HT(4) receptor by radioligand binding and functional activity using guinea-pig ileum and human colon circular muscle preparations and also in the mouse whole gut transit test. KEY FINDINGS: The three compounds all had agonist properties at the 5-HT(4) receptor but their efficacy differed in the different functional tests. Compound 3 had the highest affinity for the 5-HT(4) receptor and was a full agonist at relaxing human colon circular muscle with efficacy closest to 5-HT. Compounds 1 and 2 were partial agonists in this assay with lower efficacies; compound 2 was a full agonist in the guinea-pig ileum assay whereas compound 3 was a partial agonist. Compounds 1 and 2 also showed activity in the mouse gut transit assay while compound 3 had no activity. CONCLUSIONS: Of the compounds tested, compound 3 was the most promising 5-HT(4) receptor agonist and the results highlight the value of using human tissue in functional tests when assessing compounds for potential activity.


Assuntos
5-Metoxitriptamina/farmacologia , Colo/efeitos dos fármacos , Íleo/efeitos dos fármacos , Indóis/farmacologia , Contração Muscular/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Receptores 5-HT4 de Serotonina/metabolismo , 5-Metoxitriptamina/análogos & derivados , Animais , Feminino , Trânsito Gastrointestinal/efeitos dos fármacos , Cobaias , Humanos , Hidroxilaminas/farmacologia , Camundongos , Camundongos Endogâmicos
17.
Wei Sheng Yan Jiu ; 36(4): 505-7, 2007 Jul.
Artigo em Chinês | MEDLINE | ID: mdl-17953223

RESUMO

OBJECTIVE: To investigate the effects of hydroxylammonium nitrate (HAN) on the blood system in rats. METHODS: A total of 160 rats were randomly divided into three HAN treated groups and one negative control group, each group included 40 rats. Different doses of HAN at 6.97, 13.93 and 27.86mg/kg were administered to the three treated groups by intraperitoneal injection, and the control group was treated with 0.9% saline, the treatment had been performed every other day for 13 weeks. After the last treatment, 30 rats of each group were sacrificed and the rest were kept for another 4 weeks for recovery. Hematological parameters, reticulocyte and marrow cells were observed and measured. RESULTS: For hematological parameters, the main changes were the decrease of RBC and HGB level and the increase of WBC at the end of the administration (P < 0.05). The reticulocyte values were obviously increase along with the increasing HAN dosage compared with those of control group (P < 0.01). For bone marrow cells observation, the ratio of erythrocytic line increased, and the ratio of granulocytes/erythrocyte was lower than that of control group (P < 0.05). After 4 weeks' recovery period, no obviously changes were observed for hematological parameters, reticulocyte and marrow cells. CONCLUSION: HAN has toxic effect on the blood system in rats for long-term exposure.


Assuntos
Sistema Hematopoético/efeitos dos fármacos , Hidroxilaminas/toxicidade , Nitratos/toxicidade , Animais , Poluentes Ambientais/toxicidade , Feminino , Hemoglobinas/efeitos dos fármacos , Leucócitos/efeitos dos fármacos , Masculino , Distribuição Aleatória , Ratos , Ratos Wistar , Reticulócitos/efeitos dos fármacos
18.
Chem Pharm Bull (Tokyo) ; 54(9): 1340-3, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16946550

RESUMO

An effective procedure for decontamination of beta-lactam antibiotic residues or contaminants in the pharmaceutical manufacturing environment was investigated. Decontamination with solutions of hydrochloric acid, sodium hydroxide, hydrogen peroxide and hydroxylamine as agents for degradation was assessed. According to the results, the beta-lactam antibiotics were significantly degraded with sodium hydroxide and hydroxylamine. From the structural analysis of the degradation products of a cephem antibiotic, cefpodoxime proxetil, it was found that hydroxylamine degraded the beta-lactam structure under mild conditions, while sodium hydroxide did not. Therefore, hydroxylamine was considered an appropriate decontamination agent for beta-lactam antibiotics.


Assuntos
Antibacterianos/química , Descontaminação/métodos , Indústria Farmacêutica , Manufaturas , Preparações Farmacêuticas , beta-Lactamas/química , Antibacterianos/síntese química , Concentração de Íons de Hidrogênio , Hidroxilaminas/química , Estrutura Molecular , Hidróxido de Sódio/química , beta-Lactamas/síntese química
19.
J Pharm Biomed Anal ; 39(3-4): 724-9, 2005 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-15951147

RESUMO

Methoxyamine (MX) is a potential new anti-cancer drug. In this paper, a quantitative HPLC-UV method for MX using 4-(diethylamino)benzaldehyde (DEAB) as a derivatizing agent has been developed and validated. The studies showed that MX reacts with DEAB under acidic conditions to form protonated 4-(diethylamino)benzaldehyde o-methyloxime (DBMOH+). The equilibrium between DBMOH+ and its conjugate base 4-(diethylamino)benzaldehyde o-methyloxime (DBMO) is affected by both buffer concentration and organic solvent content in the solution. The method developed uses a reversed phase C18 column for the separation of MX derivatives, an internal standard benzil for method calibration, and a UV detector at a wavelength of 310 nm for analyte detection. The MX derivatives can be resolved in ca. 20 min. The method has a linear calibration range from 0.100 to 10.0 microM with a correlation coefficient of 0.999 for MX and a detection limit of 5 pmol with a 50 microl sample size. The intra-assay and inter-assay precision expressed in terms of percent relative standard deviation were < or =5 and 8%; and the intra-assay and inter-assay accuracy defined as the measured value divided by the accepted value multiplied by 100% were 94.2-100 and 92.6-111%, respectively. This method may be used for the analysis of MX in pharmaceutical preparations.


Assuntos
Benzaldeídos/análise , Cromatografia Líquida de Alta Pressão/métodos , Hidroxilaminas/análise , Espectrofotometria Ultravioleta/métodos , Ácido Acético/análise , Antineoplásicos/análise , Antineoplásicos/química , Benzaldeídos/química , Soluções Tampão , Calibragem , Química Orgânica , Química Farmacêutica/métodos , Cromatografia/métodos , Cromatografia Líquida , DNA/química , Reparo do DNA , Indústria Farmacêutica/métodos , Modelos Químicos , Fenômenos de Química Orgânica , Reprodutibilidade dos Testes , Solventes , Temperatura , Fatores de Tempo , Raios Ultravioleta
20.
Virology ; 210(1): 20-8, 1995 Jun 20.
Artigo em Inglês | MEDLINE | ID: mdl-7793071

RESUMO

Influenza virus hemagglutinin (HA) subtype H7 expressed from a baculovirus vector in insect cells requires cysteine residues for palmitoylation. Mutant HA devoid of fatty acids shows hemagglutinating and hemolytic activities almost identical to those of the acylated wild-type HA (wt). Using a membrane mixing assay (R18), neither the kinetics nor the pH dependence of fusion induced by wt or mutant HA was significantly different from virus-induced fusion. HA-induced fusion of insect cells with human erythrocyte ghosts could also be demonstrated by a cytoplasmic content mixing assay. Both species of recombinant HA induced the flow of lucifer yellow from preloaded ghosts into the cytoplasm of HA-bearing cells. This indicates that membrane fusion mediated by wild-type and fatty-acid-free HA includes both leaflets of the lipid bilayers. Hydroxylamine treatment of wt HA (H7) and fatty-acid-free mutant HA present in lysates of insect cells led to the complete inhibition of hemolytic activity. Deacylation of spike proteins by NH2OH treatment of virus particles resulted in a block of hemolytic activity in influenza virus subtypes H7 and H10 as well as of that in the togaviruses Semliki Forest and Sindbis virus. However, the same treatment did not affect subtypes H2 and H3 or two vesicular stomatitis virus serotypes. With such a differential effect whether or not fatty acids are present in the spike proteins of the different virus particles, hydroxylamine must have other effects than just deacylation, and therefore seems unsuitable for the study of the biological functions of acylproteins.


Assuntos
Fusão Celular , Membrana Eritrocítica/fisiologia , Hemaglutininas Virais/fisiologia , Hidroxilaminas/farmacologia , Vírus da Influenza A/imunologia , Acilação , Sequência de Aminoácidos , Animais , Linhagem Celular , Membrana Eritrocítica/imunologia , Hemaglutininas Virais/biossíntese , Hemaglutininas Virais/efeitos dos fármacos , Humanos , Concentração de Íons de Hidrogênio , Hidroxilamina , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/efeitos dos fármacos , Proteínas Recombinantes/metabolismo , Spodoptera , Transfecção
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA